Trifluridine and Tipiracil Hydrochloride

DRUG14 trials

Sponsors

City of Hope Medical Center, Emory University, M.D. Anderson Cancer Center, Academic and Community Cancer Research United, Mayo Clinic

Conditions

Advanced Bile Duct CarcinomaAdvanced Colorectal CarcinomaAdvanced Gallbladder CarcinomaAdvanced Malignant Solid NeoplasmClinical Stage IIA Esophageal Adenocarcinoma AJCC v8Clinical Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage III Esophageal Adenocarcinoma AJCC v8Clinical Stage III Gastric Cancer AJCC v8

Phase 1

Trametinib and Trifluridine and Tipiracil Hydrochloride in Treating Patients With Colon or Rectal Cancer That is Advanced, Metastatic, or Cannot Be Removed by Surgery

CompletedNCT03317119

City of Hope Medical CenterMetastatic Colon Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Rectal Carcinoma +22

Start: 2018-04-11End: 2023-07-14Updated: 2024-04-08

TAS102 in Combination With NAL-IRI in Advanced GI Cancers

Active, not recruitingNCT03368963

Emory UniversityColorectal Adenocarcinoma, Gastric Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma +11

Start: 2018-01-30End: 2025-11-28Target: 64Updated: 2025-01-07

TAS-102 With Concurrent Radiation for the Treatment of Untreated Resectable Stage II-III Rectal Cancer

Active, not recruitingNCT04104139

OHSU Knight Cancer InstituteRectal Adenocarcinoma, Stage IIA Rectal Cancer AJCC v8, Stage IIB Rectal Cancer AJCC v8 +4

Start: 2019-12-11End: 2026-05-31Updated: 2025-10-27

Trifluridine/Tipiracil and Talazoparib for the Treatment of Patients With Locally Advanced or Metastatic Colorectal or Gastroesophageal Cancer

RecruitingNCT04511039

Roswell Park Cancer InstituteAdvanced Malignant Solid Neoplasm, Clinical Stage III Gastroesophageal Junction Adenocarcinoma, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma +26

Start: 2021-06-08End: 2027-04-01Target: 45Updated: 2026-03-02

A Vaccine (PolyPEPI1018 Vaccine) and TAS-102 for the Treatment of Metastatic Colorectal Cancer

CompletedNCT05130060

Mayo ClinicMetastatic Colon Adenocarcinoma, Metastatic Colorectal Adenocarcinoma, Metastatic Colorectal Carcinoma +8

Start: 2022-01-10End: 2023-06-11Updated: 2024-08-14

Phase 2

Circulating Cell-Free Tumor DNA Testing in Guiding Treatment for Patients With Advanced or Metastatic Colorectal Cancer

Active, not recruitingNCT03844620

M.D. Anderson Cancer CenterRefractory Colorectal Carcinoma, Stage IIIA Colorectal Cancer AJCC v8, Stage IIIB Colorectal Cancer AJCC v8 +6

Start: 2019-01-29End: 2026-08-31Updated: 2026-01-09

Binimetinib and Palbociclib or TAS-102 in Treating Patients With KRAS and NRAS Mutant Metastatic or Unresectable Colorectal Cancer

CompletedNCT03981614

Academic and Community Cancer Research UnitedMetastatic Colorectal Carcinoma, Stage IVA Colorectal Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8 +3

Start: 2019-10-29End: 2024-07-02Updated: 2024-08-22

Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer

Active, not recruitingNCT03992456

Academic and Community Cancer Research UnitedMetastatic Colon Adenocarcinoma, Metastatic Colorectal Carcinoma, Metastatic Rectal Adenocarcinoma +27

Start: 2020-04-24End: 2024-10-07Updated: 2024-05-21

Trifluridine/Tipiracil and Irinotecan for the Treatment of Advanced Refractory Biliary Tract Cancer

CompletedNCT04072445

Mayo ClinicAdvanced Bile Duct Carcinoma, Advanced Gallbladder Carcinoma, Refractory Bile Duct Carcinoma +15

Start: 2019-10-18End: 2021-08-13Updated: 2023-08-09

Use of Trifluridine/Tipiracil and Oxaliplatin as Induction Chemotherapy for the Treatment of Resectable Esophageal or Gastroesophageal Junction (GEJ) Adenocarcinoma

CompletedNCT04097028

Roswell Park Cancer InstituteClinical Stage IIA Esophageal Adenocarcinoma AJCC v8, Clinical Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Adenocarcinoma AJCC v8 +13

Start: 2019-12-20End: 2025-02-05Updated: 2025-04-29

TAS-102, Irinotecan, and Bevacizumab for the Treatment of Pre-treated Metastatic or Unresectable Colorectal Cancer, the TABAsCO Study

CompletedNCT04109924

Roswell Park Cancer InstituteAdvanced Colorectal Carcinoma, Metastatic Colon Adenocarcinoma, Metastatic Rectal Adenocarcinoma +24

Start: 2019-12-27End: 2024-09-05Updated: 2026-02-10

TAS-102 and Oxaliplatin for the Treatment of Refractory Stage IV Colon Cancer

Active, not recruitingNCT04294264

Rutgers, The State University of New JerseyMetastatic Colorectal Carcinoma, Recurrent Colon Carcinoma, Refractory Colorectal Carcinoma +3

Start: 2019-02-12End: 2026-03-27Target: 50Updated: 2024-11-18

Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer

RecruitingNCT04660760

Academic and Community Cancer Research UnitedClinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastric Cancer AJCC v8 +28

Start: 2021-06-16End: 2026-05-31Target: 116Updated: 2024-04-01

Tucatinib Combined with Trastuzumab and TAS-102 for the Treatment of HER2 Positive Metastatic Colorectal Cancer in Molecularly Selected Patients, 3T Study

WithdrawnNCT05356897

Academic and Community Cancer Research UnitedMetastatic Colon Adenocarcinoma, Metastatic Colorectal Adenocarcinoma, Metastatic Rectal Adenocarcinoma +3

Start: 2023-10-31End: 2024-09-17Updated: 2024-09-19

Related Papers

Abstract 6762: A novel therapeutic approach for targeting p53-mutant cancers by leveraging DNA damage response vulnerabilities

Cancer Research2026-04-03

ACCRU-GI-1810: Trifluridine/tipiracil (FTD-TPI) or paclitaxel (PAC) in combination with ramucirumab (RAM) for patients (pts) with previously treated advanced gastroesophageal adenocarcinoma (GEA)—An investigator-initiated, randomized non-inferiority phase 2 study.

Journal of Clinical Oncology2026-01-10

Abstract B001: Effective targeting p53 mutant pancreatic cancer by novel drug-combination strategy leveraging their DNA damage liabilities

Cancer Research2025-09-28

Abstract P3-08-27: Novel Combination Immune Therapy for Metastatic Breast Cancers leveraging weaknesses in DNA damage response in p53 Mutant cancer

Clinical Cancer Research2025-06-13

Phase 1b study to assess the safety of neoadjuvant trifluridine/tipiracil with concurrent radiation in resectable stage II/III rectal cancer: Initial results of the FIERCE study.

Journal of Clinical Oncology2025-05-28

Abstract 5991: Novel triple-drug combination strategy for p53 mutant cancers leveraging their DNA damage response liabilities

Cancer Research2025-04-21

Trifluridine/Tipiracil and Oxaliplatin as Induction Chemotherapy in Resectable Esophageal and Gastroesophageal Junction Adenocarcinoma: A Phase II Study

Cancer Medicine2025-04-01

TAS-102, Irinotecan, and bevacizumab in pre-treated metastatic colorectal cancer (TABAsCO), a phase II clinical trial.

2024-09-072 citations

A randomized study evaluating tailoring of advanced/metastatic colorectal cancer (mCRC) therapy using circulating tumor DNA (ctDNA): TACT-D.

Journal of Clinical Oncology2024-06-05

Abstract 7590: Novel therapeutic approach for targeting p53 mutant colorectal cancers by affecting post-replicative DNA repair

Cancer Research2024-03-22

Phase II Trial of Trifluridine/Tipiracil Plus Irinotecan in Patients with Advanced, Refractory Biliary Tract Carcinoma

The Oncologist2023-06-201 citations

PolyPEPI1018 vaccine in combination with TAS-102 in participants with late-stage microsatellite-stable metastatic colorectal cancer (MSS mCRC): A phase Ib study to evaluate safety, tolerability, immunogenicity and efficacy (OBERTO-201).

Journal of Clinical Oncology2023-06-012 citations

OniLon: Phase II trial of trifluridine/tipiracil (TAS-102) and nanoliposomal irinotecan (nal-IRI) in advanced colorectal cancer.

Journal of Clinical Oncology2023-06-012 citations

Phase II study of biweekly TAS-102, irinotecan and bevacizumab in pre-treated metastatic colorectal cancer (TABAsCO).

Journal of Clinical Oncology2023-06-01

Effects of prior therapies on outcomes with trifluridine/tipiracil in patients with metastatic gastric/gastroesophageal junction cancer in a randomized phase III trial (TAGS)

Journal of Cancer Research and Clinical Oncology2023-05-222 citations

Abstract CT146: Trifluridine/tipiracil (FTD/TPI) and oxaliplatin as induction chemotherapy (IC) in resectable esophageal and gastroesophageal junction adenocarcinoma (EGAC): Preliminary results from a phase II study

Cancer Research2023-04-14

Phase II study of TAS-OX (TAS-102 and oxaliplatin) plus bevacizumab for late-line colorectal cancer.

Journal of Clinical Oncology2023-01-241 citations

Phase Ib open-label study to evaluate safety, tolerability, immunogenicity, and efficacy of multiple subcutaneous injections of PolyPEPI1018 vaccine as an add-on immunotherapy to TAS-102 in participants with late-stage microsatellite-stable metastatic colorectal cancer (MSS mCRC; OBERTO-201).

Journal of Clinical Oncology2023-01-241 citations

Phase 1b study to assess the safety of neoadjuvant trifluridine/tipiracil with concurrent radiation in resectable stage II/III rectal cancer.

Journal of Clinical Oncology2023-01-241 citations

A phase I clinical trial of trametinib in combination with TAS-102 in patients with chemotherapy-resistant RAS-mutated (PIK3CA/PTEN-wild type) metastatic colorectal cancer.

Journal of Clinical Oncology2022-06-01

7 more papers not shown